Presley Gerber’s Passing Raises Addiction Recovery Concerns

Presley Gerber, son of Cindy Crawford and Rande Gerber, passed away at the age of 27, sparking renewed discussions about overdose risk and the challenges faced in addiction recovery. His death occurred at a rehabilitation facility in California, confirmed by the Los Angeles County Medical Examiner’s Office.

The family requested privacy during this challenging period. While his official cause of death remains unconfirmed, reports indicate a cardiac arrest was reported at the facility where he resided. An autopsy has been completed, but the cause is pending further tests.

Presley Gerber had shared his struggles with substance use and mental health challenges publicly. Nicholas Kardaris, Ph.D., an expert from the New York Center for Living, shared insights into possible risks of relapse and complications faced in recovery.

Risks in Recovery

While Gerber’s cause of death is undetermined, Kardaris cautioned against assumptions. Possible reasons might include a medical or cardiac issue, a previously undiagnosed condition, or a medication-related complication.

“Young individuals can unexpectedly pass away, particularly if there’s an undetected health issue,” Kardaris noted.

Cardiac episodes may be triggered by certain medications, especially with underlying conditions.

Being in rehab does not assure resolution of addiction issues, as Kardaris emphasized. Treatment centers strive to manage risks associated with addiction, relapse, and withdrawal complications, but no system is flawless.

Withdrawal Dangers

During rehab, withdrawal itself can pose risks varying by substance and dependency levels. Withdrawal is risky, especially from benzodiazepines like Valium or Xanax, or alcohol without adequate supervision, which can provoke seizures and dangerous complications. While uncomfortable, opioid withdrawal is generally not fatal.

Kardaris explained, “Opioid users risk overdose post-detox due to reduced tolerance, which makes previously safe amounts potentially lethal.”

Ibogaine Treatment Considerations

Gerber had discussed undergoing ibogaine treatment in Mexico. Kardaris highlighted ibogaine’s non-approval by the FDA for U.S. medical use. While researched for possible benefits in treating opioid dependency, uncertainty about its safety and effectiveness persists.

Ibogaine, along with ketamine and ayahuasca, are psychoactive treatments gaining interest but remain unregulated. Differing oversight and evidence levels for these substances require further research.

Choosing a Treatment Program

Families must verify a center’s licensure and ensure qualified medical personnel are involved. Protocols for handling withdrawal, medication, and emergencies should be intact.

“Families need to ensure treatment programs are reputable and staffed with trained experts,” noted Kardaris.

It is crucial to ensure that the treatment plan is reliable and that professionals involved have a respected track record.